Clinical trial
Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial…
NCT00023699 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00023699 |
|---|---|
| Title | Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
| Official title | A Phase II Trial of ZD1839 (Iressa) (NSC# 715055) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | gefitinib |
| Start date | Aug 1, 2001 |
| Completion | May 1, 2006 |
| First posted | Oct 15, 2003 |
| Last update posted | Jun 24, 2013 |
| Countries | Australia, Canada, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: